Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Pleased to share our new paper out today in the British Journal of Haematology.
This is a post-hoc analysis of the BEYOND trial specifically looking at the proportion of NTDT patients that reached and sustained a hemoglobin level of >10 g/dL while on ß, reflecting clinically meaningful impact considering this would now place them in the ‘safe zone’.”
Read the full article in BJHaem.
Article: Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial
Authors: Khaled Musallam X, Ali T. Taher, John B. Porter, Antonis Kattamis, Mrudula B. Glassberg, Luciana Moro Bueno, Patricia Martin-Regueira, Marta Reverte, Loyse Felber Medlin, Matthew Dyer, Kefeng Wang, Maria Domenica Cappellini
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 8, 2026, 04:50Marc Carrier: Celebrating 20 Years with ASH CRTI
-
Aug 8, 2026, 04:37Megan Adediran: Building Confidence for a Life Beyond Haemophilia
-
Aug 8, 2026, 04:32Megan Kavanaugh Roussos: Airborne Medical Expands Portfolio with WoundClot Advanced Hemostatic Technology
-
Aug 8, 2026, 04:25Maymoon Madkhali։ First Report of a Rare D– – Blood Phenotype in Saudi Arabia
-
Aug 8, 2026, 04:13Alexandra Bernal: Uncovering the Anticoagulant Role of Factor V in Hemophilia A
-
Aug 8, 2026, 04:03Wellington Fernandes: Honored to Join the Faculty of Medicine of USP as Professor of Hematology
-
Aug 8, 2026, 04:01Noa Ezra: How Senescent Cardiac Cells Drive a Pro-Thrombotic State
-
Aug 8, 2026, 03:56Omid Khalafi: PCT – The Platelet Parameter Almost Everyone Ignores
-
Aug 7, 2026, 16:26Shayan Mohammadmoradi: Excited to Co-Chair the 2028 Hemostasis Gordon Research Seminar